APA (7th ed.) Citation

Kato, M., Nakagome, K., Baba, T., Sonoyama, T., Okutsu, D., Yamanaka, H., . . . Inoue, T. (2023). Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, phase 2 clinical trial. Psychiatry & Clinical Neurosciences, 77(9), 497. https://doi.org/10.1111/pcn.13569

Chicago Style (17th ed.) Citation

Kato, Masaki, Kazuyuki Nakagome, Takamichi Baba, Takuhiro Sonoyama, Daiki Okutsu, Hideki Yamanaka, Ryosuke Shimizu, Tomoko Motomiya, and Takeshi Inoue. "Efficacy and Safety of Zuranolone in Japanese Adults with Major Depressive Disorder: A Double‐blind, Randomized, Placebo‐controlled, Phase 2 Clinical Trial." Psychiatry & Clinical Neurosciences 77, no. 9 (2023): 497. https://doi.org/10.1111/pcn.13569.

MLA (9th ed.) Citation

Kato, Masaki, et al. "Efficacy and Safety of Zuranolone in Japanese Adults with Major Depressive Disorder: A Double‐blind, Randomized, Placebo‐controlled, Phase 2 Clinical Trial." Psychiatry & Clinical Neurosciences, vol. 77, no. 9, 2023, p. 497, https://doi.org/10.1111/pcn.13569.